Cell Death and Survival

PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

Eric G. Bluemn1,2, Elysia Sophie Spencer1, Brigham Mecham2,3, Ryan R. Gordon2, Ilsa Coleman2, Daniel Lewinshtein2,5, Elahe Mostaghel1,2, Xiaotun Zhang1, James Annis1,4, Carla Grandori1,2,4, Christopher Porter5, and Peter S. Nelson1,2

Abstract
Metastatic prostate cancers generally rely on androgen receptor (AR) signaling for growth and survival, even following systemic androgen-deprivation therapy (ADT). However, recent evidence suggests that some advanced prostate cancers escape ADT by using signaling programs and growth factors that bypass canonical AR ligand-mediated mechanisms. We used an in vitro high-throughput RNA interference (RNAi) screen to identify pathways in androgen-dependent prostate cancer cell lines whose loss-of-function promotes androgen ligand-independent growth. We identified 40 genes where knockdown promoted proliferation of both LNCaP and VCaP prostate cancer cells in the absence of androgen. Of these, 14 were downregulated in primary and metastatic prostate cancer, including two subunits of the protein phosphatase 2 (PP2A) holoenzyme complex: PPP2R1A, a structural subunit with known tumor-suppressor properties in several tumor types; and PPP2R2C, a PP2A substrate-binding regulatory subunit that has not been previously identified as a tumor suppressor. We show that loss of PPP2R2C promotes androgen ligand depletion-resistant prostate cancer growth without altering AR expression or canonical AR-regulated gene expression. Furthermore, cell proliferation induced by PPP2R2C loss was not inhibited by the AR antagonist MDV3100, indicating that PPP2R2C loss may promote growth independently of known AR-mediated transcriptional programs. Immunohistochemical analysis of PPP2R2C protein levels in primary prostate tumors determined that low PPP2R2C expression significantly associated with an increased likelihood of cancer recurrence and cancer-specific mortality. These findings provide insights into mechanisms by which prostate cancers resist AR-pathway suppression and support inhibiting PPP2R2C complexes or the growth pathway(s) activated by PPP2R2C as a therapeutic strategy.

Introduction
Prostate cancer is the second leading cause of cancer-related mortality in American men (1). Most deaths are attributable to metastatic disease, a stage that exhibits high initial response rates to systemic androgen-deprivation therapy (ADT; ref. 2). Unfortunately, nearly all metastatic tumors recur as castration-resistant prostate cancers (CRPC; ref. 2). Currently available treatments of CRPC provide limited improvements in survival, though recent developments of novel immunotherapies and more potent antagonists have resulted in additional modest increases in patient longevity (3–5).

Importantly, the vast majority of CRPCs reactivate androgen receptor (AR)-mediated transcriptional networks that seem to be necessary for prostate cancer survival and growth. The maintenance of AR-pathway activity has been shown to occur through a variety of mechanisms, including but not limited to transcriptional and genomic amplification of AR, mutations of AR that allow promiscuous ligand binding, generation of constitutively active AR splice variants, de novo synthesis of intratumoral androgens, and transactivation of the AR by intracellular signal transduction programs (6, 7). However, there is mounting evidence that alternative mechanisms can promote CRPC progression independent of AR activation. Several recent in vitro and in vivo studies provide evidence that phosphoinositide 3-kinase (PI3K) pathway signaling is sufficient for CRPC survival in the setting of low or absent AR activity (8, 9). With clinical efforts focused on extinguishing AR activity through enhanced AR blockade and the elimination of AR

Authors' Affiliations: 1School of Medicine, University of Washington; 2Division of Human Biology, Fred Hutchinson Cancer Research Center; 3Sage Bionetworks; 4Institute for Stem Cell and Regenerative Medicine; and 5Department of Urology, Virginia Mason Medical Center, Seattle, Washington

Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

Corresponding Author: Peter S. Nelson, Division of Human Biology, Fred Hutchinson Cancer Research Center, Mailstop D4-100, 1100 Fairview Ave N, Seattle, WA 98109. Phone: 206-667-3377; Fax: 206-667-2917; E-mail: pnels@fhcrc.org
doi: 10.1158/1541-7786.MCR-12-0710
©2013 American Association for Cancer Research.
ligands, additional androgen pathway-independent resistance mechanisms are likely to emerge.

To identify genes and pathways that modify prostate cancer growth in the context of suppressed AR signaling, we conducted in vitro high-throughput RNA interference (RNAi) screening (HTRS) using a siRNA library designed to target 6,650 individual genes representing several major ontology classes including cellular kinases, phosphatases, transcription factors, and growth factor receptors. We hypothesized that a subset of genes and gene networks could confer a castration-resistant phenotype in prostate cancer cells previously dependent upon androgen-mediated signaling for growth and survival. To prioritize candidate hits for clinical relevance, the HTRS results were cross-referenced with gene expression datasets collected from primary prostate cancers and cases of metastatic CRPC. This evaluation revealed that a subset of transcripts encoding proteins comprising the protein phosphatase 2A (PP2A) complex were enriched for a phenotype of AR ligand-independent growth promotion in the HTRS experiments and were also downregulated in a subset of primary and metastatic prostate carcinomas.

PP2A is a highly conserved serine/threonine phosphatase that has a broad spectrum of biologic roles including the negative regulation of signal transduction, cell-cycle progression, and gene expression (10, 11). The PP2A holoenzyme is composed of a core dimer—consisting of a catalytic subunit (PPP2CA/PPP2CB) and a structural subunit (PPP2R1A/PPP2R1B)—which form a heterotrimeric complex with a "B" subunit. The B subunit originates from one of 18 genes grouped into 4 structurally unrelated families and is thought to dictate substrate specificity, cellular localization, and enzymatic activity of the PP2A complex (12). Loss of PP2A activity is often a transforming event, which is perhaps most obvious in cells expressing the SV40 small t antigen (SV40ST) viral oncogene. SV40ST competes with B subunits to bind the PPP2CA–PPP2R2C heterodimer (13); SV40ST binding is required for viral transformation (14). In addition, nonviral mechanisms of PP2A inhibition are well documented in a wide variety of human cancers, and de novo loss of PP2A activity, or modulating signaling programs regulated via PP2A, should be evaluated for therapeutic effects in patients with CRPCs.

Materials and Methods

Cell culture and siRNA transfection

LNCaP and VCaP cell lines were obtained from American Type Culture Collection and maintained in androgen-replete phenol red-free RPMI-1640 + 10% FBS (Life Technologies) + 1% PenStrep (Life Technologies). Cells were used within 6 months of resuscitation. One day before transfection cells were passaged into androgen-depleted phenol red-free Optimem (Life Technologies) supplemented with 3% charcoal-dextran–stripped FBS (CSS) onto Matrix Screen Mate tissue culture-treated 384-well plates (Thermo Scientific) using the densities determined during the feasibility study on a FluidX XRD384 peristaltic liquid handler in a total well volume of 50 μL.

Experimental working plates were prepared by first stamping 10 μmol/L siRNA library stocks into dry 384-well Abgene 1055-384-well microarray plates (Thermo Scientific) using a Vario workstation (Cybio) equipped with a 25 μL 384-well tip head. A sidecar plate containing UNI1 nontargeting control, Kif11, and assay-specific controls (Sigma-Aldrich) was then replicated on each experimental working plate on the Cybio Vario workstation. OptiMEM and Lipofectamine RNAiMax (Life Technologies) were added to the experimental working plates on a FluidX XRD384 peristaltic liquid handler using predefined metrics determined via the Quellos HTS Feasibility assay. Transfections were carried out by adding 5 μL for VCAP and 0.625 μL for LNCAP, respectively, from each experimental working plate onto 3 replicate cell plates using the CyBio Vario workstation.

Cell viability was assessed after the 96-hour incubation with the addition of Cell Titer-Glo (Promega) on the FluidX 384 liquid handler. Luminescence was read using an Envision HTS multilabel reader (PerkinElmer).

Deconvoluted siRNA experiments were carried out in 96-well plates using transfection conditions scaled-up from 384-well experiments in a total volume of 125 μL. Kif11, UNI1 nontargeting control, and PPP2R2C-targeting siRNA were purchased from Sigma-Aldrich. Ninety-six hours after transfection, cell viability was assessed by adding Cell Titer-Glo and measuring luminescence on a Synergy2 multwell plate reader (BioTek), siRNA sequences can be found in Supplementary Table S2.

Dasatinib was purchased from Chemitek, R1881 was purchased from PerkinElmer, U0126 was purchased from Cell Signaling Technology, and LY294002 was purchased...
from Medivation Inc. MDV3100 was obtained as a gift from Medivation Inc.

**Statistical analysis of siRNA experiments**

The data from the HTRS experiments were defined as the raw signal luminescence measured by the Envision HTS multilabel reader. For each sample, the raw intensities were transformed to Z scores within each plate. The median standardized value for each gene was then used as an input for the downstream analysis. To downweight the influence of siRNAs undergoing large changes on the parameters used to define the Z score transformation, the estimated means and variances were defined after removing the top and bottom 2.5% of the data within each plate.

Analysis of follow-up siRNA screens and quantitative real-time PCR (qRT-PCR) data was conducted in Prism 4.0 software (GraphPad). Raw luminescence was normalized to the mean luminescence value of siUNI for each cell line. Treatment effect was measured by normalizing raw luminescence values in treatment groups to the median luminescence value in the vehicle-treated group. Statistical analysis was conducted using an unpaired two-sided Student t test using Welch’s correction to determine significance.

The statistical significance of PPP2R2C expression in gene expression microarray data and tissue microarray (TMA) nuclear intensity staining was conducted using a Student t test. Multivariate analysis assessing the association between PPP2R2C staining intensity and patient survival data was conducted using the Proc-Mixed procedure in SAS (SAS Institute) adjusting for the random effects of preoperative PSA level and variances were downweighted for the downstream analysis. To downweight the influence of siRNAs undergoing large changes on the parameters used to define the Z score transformation, the estimated means and variances were defined after removing the top and bottom 2.5% of the data within each plate.

**Quantitative real-time PCR**

RNA was isolated from cells 24 hours posttransfection using the RNeasy Kit (Qiagen Inc.) and cDNA was generated with Superscript II (Life Sciences) as per protocol. qRT-PCR reactions were carried out in triplicate using an Applied Biosystems 7900 sequence detector with SYBR Green PCR master mix (Life Technologies). Primers were designed using PrimerQuest (IDT), and all reactions were normalized to the expression of the housekeeping gene Rpl13a. A water-negative control did not produce significant amplification product. PCR primer sequences can be found in Supplementary Table S3. Statistical analysis was conducted using an unpaired two-sided Student t test using Welch’s correction to determine significance.

**Gene expression microarrays**

Agilent 44K whole human genome expression oligonucleotide microarrays (Agilent Technologies, Inc.) were used to profile 14 human primary prostate tumors and 54 castration-resistant prostate metastases from 11 patients (the patient cohort is described in detail by Holcomb and colleagues (18)). The tumor samples were laser-capture microdissected, and total RNA isolated and amplified as described previously (19). Probe labeling and hybridization was conducted following the Agilent suggested protocols and fluorescent array images were collected using the Agilent DNA microarray scanner G2565BA. Agilent Feature Extraction software was used to grid, extract, and normalize data. The resulting data were then combined with a publicly available dataset consisting of 15 normal prostate samples from untreated cancer-free patients (20). Expression ratios were log2 scaled and mean-centered across each gene.

**Protein collection and immunoblotting**

Protein was collected from tissue culture by lysing adherent cells with a cell lysis buffer (1.5 mol/L urea, 1% SDS, 1% NP-40, 2% Tween20, 250 mmol/L NaCl, and PBS) supplemented with 1x phosphatase inhibitors (PhosStop; Roche Diagnostics) and 1x protease inhibitor cocktail (Complete Mini; Roche Diagnostics). Protein was quantified per protocol using a bicinchoninic acid assay (Thermo Scientific). Normalized cell lysates were loaded onto a 12% NuPAGE Bis-Tris gel (Life Technologies) in MES [2-(N-Morpholino)ethanesulfonic acid] buffer. Protein was transferred to nitrocellulose membranes using a semi-dry transfer apparatus and Tris/CAPS buffer. Immunoblots were probed with primary antibodies targeting AKT (Cell Signaling Technology; #9272), phospho-AKT (Cell Signaling Technology; #4058), Erk1/2 (Sigma; M5670), diphosphorylated-Erk1/2 (Sigma; M9692), PP2R2C (Abnova; clone 6D1), Src (Cell Signaling Technology; #2110), and phospho-Src (Cell Signaling Technology; #2101). Horseradish-peroxidase–conjugated secondary antibodies (Thermo Scientific) were used in conjunction with Supersignal West Pico Chemiluminescent substrate (Thermo Scientific) to visualize protein targets. Membranes were then stripped for 15 minutes in Stripping Buffer (Thermo Scientific) and reprobed with antiactin antibody (Santa Cruz Biotechnology; sc-1616) as a loading control.

**Tissue microarray construction**

Prostate specimens were collected from a cohort of 100 men who underwent radical prostatectomy at Virginia Mason Medical Center (Seattle, WA) between 1954 and 1997 (Supplementary Table S1). Tissue specimens were formalin-fixed and embedded in paraffin following surgical resection. Patients were monitored for both biochemical recurrence (PSA > 0.2 ng/mL following radical prostatectomy) and pathologic recurrence [pelvic disease, regional lymph node metastasis, distant metastasis, or prostate cancer-specific mortality (PCSM)]. Tissue diagnosis or overt radiographic signs confirmed the presence of disease recurrence. To classify patients as developing PCSM, death certificates were obtained and prostate cancer had to be the first listed cause of death. Thirty-four patients were identified with known adverse outcomes of either distant metastasis or
PP2R2C-Mediated Prostate Cancer Growth

PCSM. These patients were matched by age, PSA, and time since surgery at a 1:2 ratio with 66 patients who had undergone radical prostatectomy and had no evidence of recurrence. Fred Hutchinson Cancer Research Center’s Internal Review Office granted approval for the use of patient tissue samples and deidentified clinical data for research purposes according to the requirements of the Human Subjects Institutional Review Board guidelines (IRB #7624, Approval dates: 11/18/11-11/16/12).

Representative formalin-fixed, paraffin-embedded (FFPE) blocks of radical prostatectomy specimens were selected. A genitourinary pathologist reviewed hematoxylin and eosin (H&E)–stained sections from representative FFPE blocks collected from each patient. Prostate cancer was confirmed and assigned a Gleason score. The H&E-stained sections were marked to identify the regions of cancer and benign glandular epithelia and 3 TMAs were constructed with 38 mm × 25 mm × 12 mm paraffin recipient blocks using a manual tissue arrayer (Beecher Instrument). Patients were represented in the TMAs by 4 0.6-mm diameter cores of tissue, 1 benign and 3 cancer, for a total of 400 biopsy cores.

Immunohistochemistry

FFPE TMAs were deparaffinized and rehydrated. Three percent hydrogen peroxide was used to quench endogenous tissue peroxidases and an avidin/biotin blocking system (Dako) was used to quench endogenous avidin/biotin. Antigen retrieval was conducted with 10 mmol/L citrate buffer, pH 6.0 in a pressure cooker. Tissue was blocked with normal serum specific to the secondary antibody (horse) and the primary antibody for PPP2R2C (clone 6D1, Abnova) was applied for 30 min at room temp, followed by biotinylated anti-mouse secondary antibodies (Dako) and ABC reagent (Vector Laboratories). 3,3′-Diaminobenzidine (DAB; Dako) was used as the chromogen and the TMA was counterstained with Meyer’s hematoxylin (Dako). PPP2R2C nuclear staining was assessed by a genitourinary pathologist and graded on a 0–3 scale, with a score of 3 representing intense nuclear staining.

Results

siRNA screen identifies modifiers of castration-resistant prostate cancer proliferation

To identify genes capable of promoting the growth of prostate cancer cells in the absence of exogenous AR ligands, we conducted a HTRS using 2 androgen-sensitive prostate cancer cell lines; LNCaP and VCaP. Briefly, cells were cultured in CSS to simulate ADT. Optimal transfection conditions were determined as previously described (21, 22). A library of siRNAs designed to inhibit the translation of 6,650 individual genes was used in an arrayed screening strategy whereby a pool of 3 siRNAs targeting each specific gene was separately introduced into replicate cell cultures (1 gene per well) in 384-well culture plates. After 96 hours of growth, cell numbers were estimated using the Cell Titer-Glo luminescence reagent. Raw luminescence signal intensity from the HTRS screen was transformed into Z scores within each plate, and median standardized Z scores for each gene were used in downstream analysis. To prioritize genes for further study, we arbitrarily set a significance threshold of Z ≥ 1.96. At this cutoff point, suppression of 380 unique genes in LNCaP and 240 unique genes in VCaP induced cell growth in the absence of exogenous androgens (Fig. 1), of which 40 induced growth in both cell lines (Table 1). Of the 40 genes whose suppression induced growth in both LNCaP and VCaP cells, 2 encoded components of the PP2A serine/threonine phosphatase complex: PPP2R2C and PPP2R1A.

PP2A subunit expression is reduced in primary and metastatic prostate cancers

To prioritize HTRS hits exhibiting potential tumor-suppressor expression patterns, we cross-referenced the screen results with transcript abundance levels determined by microarray measurements of laser-capture microdissected benign prostate epithelia (n = 15), ADT-resistant primary prostate tumors (n = 14), and CRPC metastases (n = 54). Out of the 40 proliferation-suppressor genes identified in the in vitro HTRS, 14 genes were significantly downregulated in primary and metastatic CRPC samples compared with benign prostate epithelia, including PPP2R2C and PPP2R1A (Fig. 2). Specifically, the mean expression of PPP2R2C in these primary and metastatic cancers was 3.85-fold lower (P = 0.034) and 5.69-fold lower (P < 0.001) than benign prostate epithelia, respectively. PPP2R1A expression was also decreased in metastatic prostate tumors (1.55-fold; P < 0.001).

www.aacjrournals.org Mol Cancer Res; 11(6) June 2013 571

Published OnlineFirst March 14, 2013; DOI: 10.1158/1541-7786.MCR-12-0710

Downloaded from mcr.aacrjournals.org on April 20, 2017. © 2013 American Association for Cancer Research.
We next evaluated HTRS experimental results and human prostate gene expression data for evidence of other PP2A components behaving as tumor suppressors. Previous studies have reported that suppression of the PP2A constituents PPP2CA and PPP2R2A can promote CRPC cell growth (15, 16). However, transcripts encoding these PP2A subunits were not downregulated in the primary prostate cancers we evaluated (Fig. 3A). Furthermore, transcripts encoding PPP2CA were significantly higher in metastatic CRPC (1.9-fold; \( P < 0.001 \); Fig. 3A). In the HTRS experiments, siRNAs targeting PPP2CA or PPP2R2A did not induce significant castration-resistant growth in either LuCAP or VCaP cells (Fig. 3B).

As 4 of 16 PP2A subunits tested in the HTRS experiments induced AR ligand-independent proliferation in at least one cell line (Fig. 3B), we sought to further assess the mechanism(s) by which PP2A activity contributes to this phenotype. We selected PPP2R2C for further investigation based on the findings that PPP2R2C induced significant androgen depletion-resistant proliferation in both cell lines evaluated, and PPP2R2C was the HTRS hit found to be most downregulated in castration-resistant cancers (Table 1).

### Table 1. Genes with growth-promoting effects following siRNA suppression

<table>
<thead>
<tr>
<th>Official gene symbol</th>
<th>Gene ID</th>
<th>Gene name</th>
<th>Median Z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOB</td>
<td>338</td>
<td>Apolipoprotein B (including Ag(x) antigen)</td>
<td>2.43 LNCaP 1.97 VCaP</td>
</tr>
<tr>
<td>AQPA</td>
<td>343</td>
<td>Aquaporin 8</td>
<td>2.40 LNCaP 2.26 VCaP</td>
</tr>
<tr>
<td>ART4</td>
<td>420</td>
<td>ADP-ribosyltransferase 4</td>
<td>2.03 LNCaP 2.72 VCaP</td>
</tr>
<tr>
<td>CAPN13</td>
<td>92291</td>
<td>Calpain 13</td>
<td>2.11 LNCaP 2.29 VCaP</td>
</tr>
<tr>
<td>CYP2A6</td>
<td>1548</td>
<td>Cytochrome P450, family 2, subfamily A, polypeptide 6</td>
<td>2.19 LNCaP 2.15 VCaP</td>
</tr>
<tr>
<td>DNAJB2</td>
<td>3300</td>
<td>DnaJ (Hsp40) homolog, subfamily B, member 2</td>
<td>3.79 LNCaP 2.09 VCaP</td>
</tr>
<tr>
<td>DPEP1</td>
<td>1800</td>
<td>Dipeptidase 1</td>
<td>3.22 LNCaP 2.14 VCaP</td>
</tr>
<tr>
<td>ESRRB</td>
<td>2103</td>
<td>Estrogen-related receptor ( \beta )</td>
<td>2.51 LNCaP 2.81 VCaP</td>
</tr>
<tr>
<td>GABRA2</td>
<td>2555</td>
<td>Gamma-aminobutyric acid A receptor, ( \alpha )</td>
<td>2.44 LNCaP 2.53 VCaP</td>
</tr>
<tr>
<td>GBP7</td>
<td>388646</td>
<td>Guanylate-binding protein 7</td>
<td>3.07 LNCaP 2.86 VCaP</td>
</tr>
<tr>
<td>IDS</td>
<td>3423</td>
<td>Iduronate 2-sulfatase</td>
<td>2.00 LNCaP 2.25 VCaP</td>
</tr>
<tr>
<td>KCN2D</td>
<td>3751</td>
<td>Potassium voltage-gated channel, Shal-related subfamily, 2</td>
<td>2.20 LNCaP 3.07 VCaP</td>
</tr>
<tr>
<td>KCTD5</td>
<td>54442</td>
<td>Potassium channel tetramerization domain containing 5</td>
<td>3.13 LNCaP 2.47 VCaP</td>
</tr>
<tr>
<td>KCTD12</td>
<td>115207</td>
<td>Potassium channel tetramerization domain containing 12</td>
<td>3.54 LNCaP 3.81 VCaP</td>
</tr>
<tr>
<td>KIF2C</td>
<td>11004</td>
<td>Kinesin family member 2C</td>
<td>2.01 LNCaP 2.01 VCaP</td>
</tr>
<tr>
<td>KLHL3</td>
<td>26249</td>
<td>Kelch-like 3</td>
<td>2.39 LNCaP 2.54 VCaP</td>
</tr>
<tr>
<td>KLHL13</td>
<td>90293</td>
<td>Kelch-like 13</td>
<td>3.16 LNCaP 2.42 VCaP</td>
</tr>
<tr>
<td>LAMB2</td>
<td>3913</td>
<td>Laminin, ( \beta ) 2</td>
<td>3.48 LNCaP 3.46 VCaP</td>
</tr>
<tr>
<td>MGC26694</td>
<td>284439</td>
<td>Hypothetical protein MGC26694</td>
<td>3.49 LNCaP 7.26 VCaP</td>
</tr>
<tr>
<td>MIPEP</td>
<td>4285</td>
<td>Mitochondrial intermediate peptidase</td>
<td>2.27 LNCaP 2.67 VCaP</td>
</tr>
<tr>
<td>NPM2</td>
<td>10361</td>
<td>Nucleophosmin/nucleoplasm, 2</td>
<td>2.26 LNCaP 2.43 VCaP</td>
</tr>
<tr>
<td>NR2F1</td>
<td>7025</td>
<td>Nuclear receptor subfamily 2, group F, member 1</td>
<td>2.34 LNCaP 3.45 VCaP</td>
</tr>
<tr>
<td>PAFAH1B1</td>
<td>5048</td>
<td>Platelet-activating factor acetylhydrolase, isoform ( \beta ) ( \alpha )</td>
<td>2.70 LNCaP 2.20 VCaP</td>
</tr>
<tr>
<td>PAQR4</td>
<td>124252</td>
<td>Progestin and adipoQ receptor family member IV</td>
<td>2.38 LNCaP 2.25 VCaP</td>
</tr>
<tr>
<td>PLOD2</td>
<td>5352</td>
<td>Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2</td>
<td>2.32 LNCaP 3.09 VCaP</td>
</tr>
<tr>
<td>PPP2R1A</td>
<td>5518</td>
<td>PP2A regulatory subunit A (PR65 ( \alpha ) ( \alpha ))</td>
<td>2.20 LNCaP 3.29 VCaP</td>
</tr>
<tr>
<td>PPP2R2C</td>
<td>5522</td>
<td>PP2A regulatory subunit B (PR55 ( \gamma ))</td>
<td>2.93 LNCaP 2.10 VCaP</td>
</tr>
<tr>
<td>PYGM</td>
<td>5837</td>
<td>Phosphorylase, glycogen; muscle</td>
<td>3.29 LNCaP 2.25 VCaP</td>
</tr>
<tr>
<td>RAD23A</td>
<td>5886</td>
<td>RAD23 homolog A</td>
<td>3.21 LNCaP 2.04 VCaP</td>
</tr>
<tr>
<td>RARG</td>
<td>5916</td>
<td>Retinoic acid receptor, ( \gamma )</td>
<td>2.04 LNCaP 2.05 VCaP</td>
</tr>
<tr>
<td>RHOD</td>
<td>6007</td>
<td>Rhesus blood group, D antigen</td>
<td>2.41 LNCaP 2.03 VCaP</td>
</tr>
<tr>
<td>RNF20</td>
<td>56254</td>
<td>Ring finger protein 20</td>
<td>3.01 LNCaP 2.03 VCaP</td>
</tr>
<tr>
<td>RNF144</td>
<td>9781</td>
<td>Ring finger protein 144</td>
<td>2.39 LNCaP 2.77 VCaP</td>
</tr>
<tr>
<td>SMR</td>
<td>6723</td>
<td>Spermidine synthase</td>
<td>2.34 LNCaP 2.07 VCaP</td>
</tr>
<tr>
<td>TNXB</td>
<td>7148</td>
<td>Tenascin XB</td>
<td>2.32 LNCaP 2.57 VCaP</td>
</tr>
<tr>
<td>TOPBP1</td>
<td>11073</td>
<td>Topoisomerase (DNA) II binding protein</td>
<td>2.48 LNCaP 2.22 VCaP</td>
</tr>
<tr>
<td>UBA6</td>
<td>55236</td>
<td>Ubiquitin-like modifier activating enzyme 6</td>
<td>2.01 LNCaP 2.09 VCaP</td>
</tr>
<tr>
<td>UNC5C</td>
<td>8633</td>
<td>Unc-5 homolog C</td>
<td>3.68 LNCaP 3.18 VCaP</td>
</tr>
<tr>
<td>USP21</td>
<td>27005</td>
<td>Ubiquitin specific protease 21</td>
<td>2.13 LNCaP 2.17 VCaP</td>
</tr>
<tr>
<td>ZFAND3</td>
<td>60685</td>
<td>Zinc finger, AN1-type domain 3</td>
<td>3.83 LNCaP 3.65 VCaP</td>
</tr>
</tbody>
</table>

We next evaluated HTRS experimental results and human prostate gene expression data for evidence of other PP2A components behaving as tumor suppressors. Previous studies have reported that suppression of the PP2A constituents PPP2CA and PPP2R2A can promote CRPC cell growth (15, 16). However, transcripts encoding these PP2A subunits were not downregulated in the primary prostate cancers we evaluated (Fig. 3A). Furthermore, transcripts encoding PPP2CA were significantly higher in metastatic CRPC (1.9-fold; \( P < 0.001 \); Fig. 3A). In the HTRS experiments, siRNAs targeting PPP2CA or PPP2R2A did not induce significant castration-resistant growth in either LuCAP or VCaP cells (Fig. 3B). As 4 of 16 PP2A subunits tested in the HTRS experiments induced AR ligand-independent proliferation in at least one cell line (Fig. 3B), we sought to further assess the mechanism(s) by which PP2A activity contributes to this phenotype. We selected PPP2R2C for further investigation based on the findings that PPP2R2C induced significant androgen depletion-resistant proliferation in both cell lines evaluated, and PPP2R2C was the HTRS hit found to be most downregulated in castration-resistant cancers (Table 1).
metastatic prostate cancer compared with benign epithelium (Fig. 2).

Knockdown of PPP2R2C promotes prostate cancer growth in the absence of androgens without inducing AR activity in vitro

Because the siRNA screens were conducted using pools of 3 siRNAs targeting each gene, we evaluated individual siRNA efficacy by transfecting LNCaP and VCaP with the deconvoluted pool of PPP2R2C siRNAs, designated siRNA #1-3. Suppression of PPP2R2C by gene-specific siRNA was confirmed by qRT-PCR and correlated with assays of cell proliferation. PPP2R2C knockdown by si#2 and si#3 were confirmed at the protein level in both cell lines (Fig. 4A). Scrambled control siRNAs (siUNI) did not alter PPP2R2C expression or influence cell proliferation (Fig. 4B). The positive control for cell death, siKiff11, substantially reduced the number of tumor cells in both LNCaP and VCaP experiments (Fig. 4B). As expected, exposing LNCaP or VCaP cells to androgen (R1881) stimulated proliferation and induced the AR target genes PSA, FKBP5, TMPRSS2, and ERG (in VCaP; Fig. 4B–D). siRNA#1 suppressed PPP2R2C transcripts by 10-fold in both cell lines, but did not influence cell proliferation in either line. However, both siRNA #2 and siRNA #3 reduced PPP2R2C mRNAs in LNCaP by 11.1- and 4.2-fold ($P < 0.001$), respectively (Fig. 4B and C). siRNA#2 and #3 in VCaP resulted in decreased TMPRSS2 expression (1.3-fold; $P < 0.02$) and resulted in a 1.6-fold increase in ERG expression ($P < 0.01$; Fig. 4C). Suppression of PPP2R2C with siRNA #2 and #3 in LNCaP cells did not significantly increase growth in either cell line (Supplementary Fig. S1). PPP2R2C suppression did not alter AR or PSA expression in either cell line (Fig. 4C and D).

PPP2R2C downregulated with si#3 in LNCaP and si#2 in VCaP did not affect androgen-regulated gene expression. These data indicate that the growth advantages attained from PPP2R2C knockdown were not mediated by an increase in canonical AR transcriptional activity.
To further assess the potential role of the AR in PPP2R2C-mediated prostate cancer cell growth in the context of androgen depletion, LNCaP and VCaP cells were treated with the AR antagonist MDV3100. In the absence of exogenous androgens, MDV3100 had a slight effect in reducing VCaP cell numbers after 96 hours (12%; \( P = 0.05 \)) and no discernable effect on LNCaP growth (Fig. 4E and F). As expected, MDV3100 effectively suppressed the proliferative effects induced by the synthetic androgen R1881 in both lines (Fig. 4E and F). Suppression of PPP2R2C induced cell proliferation in VCaP cells (si#2: 24%, \( P < 0.001 \); si#3: 18%, \( P = 0.002 \)) and LNCaP cells (si#2: 32%, \( P < 0.001 \); si#3: 40%, \( P < 0.001 \)) in androgen-depleted medium despite treatment with MDV3100 (Fig. 4E and F). Collectively, these experiments indicate that PPP2R2C loss is sufficient to induce AR pathway-independent proliferation in prostate cancer cells.

PPP2R2C knockdown does not mediate proliferation through activation of SRC, PI3K, or ERK1/2 signal transduction in prostate carcinoma

Previous experimentation in nonepithelial cancer models indicate that PPP2R2C may negatively regulate the activity of the v-src sarcoma viral oncogene homolog SRC (23). As SRC has been postulated to promote CRPC growth (24, 25), we hypothesized that PPP2R2C loss may promote...
castration-resistant growth in LNCaP and VCaP cells by modulating SRC phosphorylation and consequent activity. However, knockdown of PPP2RC did not result in SRC phosphorylation (Fig. 5A and B) and treatment with the SRC inhibitor dasatinib failed to inhibit castration-resistant growth induced by PPP2RC knockdown (Fig. 5C and D). Therefore, these experiments indicate that androgen depletion-resistant growth of LNCaP and VCaP cell lines following PPP2RC knockdown is not mediated through enhanced SRC activity.

We next evaluated the influence of PPP2RC in other signal transduction pathways postulated to influence CRPC growth. Specifically, we investigated the phosphorylation of ERK1/2 and protein kinase B/AKT (AKT; refs. 8, 26). Depletion of PPP2RC did not result in observable changes in the phosphorylation of ERK1/2 when compared with the scrambled control siRNA. AKT phosphorylation was slightly decreased in VCaP, but was unchanged in LNCaP (Fig. 5A and B). To confirm that PPP2RC knockdown did not induce growth through PI3K or ERK1/2 activation, cells were cotreated with pharmacologic inhibitors of these pathways and siRNAs targeting PPP2RC. Inhibition of PI3K with LY294002, or mitogen-activated protein/extracellular signal–regulated kinase (MEK) with U0126, failed to abrogate growth-induction mediated by PPP2RC knockdown (Fig. 5E–H). Therefore, it seems that PPP2RC knockdown...
influences signaling pathways capable of promoting prostate cancer cell growth that are distinct from PI3K, ERK1/2, or SRC in the setting of androgen depletion.

Decreased PPP2R2C expression is primary prostate cancers is associated with disease relapse and prostate cancer-specific mortality

Because PPP2R2C downregulation promotes castration-resistant growth, we hypothesized that PPP2R2C expression might influence long-term disease outcome in men with prostate carcinoma. To explore this hypothesis, we conducted immunohistochemical (IHC) staining for PPP2R2C on radical prostatectomy tissues from a cohort of 100 patients with documented long-term clinical outcomes that included biochemical relapse, local recurrence, distant metastases, and PCSM (Supplementary Table S1). A range of PPP2R2C protein expression was noted between individual cores, yet staining within each tumor core was largely homogenous. PPP2R2C staining of LNCaP and VCaP cell lines also showed nuclear staining (Supplementary Fig. S2). Each TMA core was categorized on the basis of IHC nuclear intensity according to a scale from 0 representing no PPP2R2C staining and a score of 3 representing high-intensity nuclear staining (Fig. 6A–D). We analyzed the impact of nuclear PPP2R2C expression on prostate cancer morbidity and mortality using the Proc Mixed model in SAS (SAS 9.3) adjusted for patient pre-surgical serum PSA levels and tumor stage at the time of prostatectomy. Lower PPP2R2C staining was significantly correlated with biochemical relapse ($P < 0.01$) and the development of distant metastases ($P < 0.001$). We also observed that PCSM was correlated with low PPP2R2C protein expression ($P = 0.048$; Table 2). Kaplan–Meier survival curves for patients with tumors expressing high PPP2R2C (MNI $\geq 1$) and those with low PPP2R2C (MNI $< 1$) revealed a survival advantage in those patients whose tumors expressed high levels of PPP2R2C (log-rank test $P = 0.045$; Fig. 6E).

Discussion

The development and clinical use of increasingly potent therapeutics targeting the AR and androgenic steroid production in prostate cancer (4, 5) is likely to select against those tumor cells relying on AR-mediated pathways for survival. Therefore, identifying AR pathway-independent prostate cancer growth and survival mechanisms will become increasingly relevant in clinical disease. Here, we provide evidence that decreased expression of the regulatory PP2A subunit, PPP2R2C, promotes CRPC growth. Importantly, growth induction was not mediated by the upregulation of the AR or androgen-regulated genes, and growth was not inhibited by treatment with the potent AR antagonist MDV3100. These data strongly suggest that PPP2R2C loss activates growth and survival pathways that bypass traditional approaches to suppress prostate cancer via the AR. Therefore, we expected to observe PPP2R2C loss in a subset of clinical prostate tumors. Multivariate regression analysis showed a statistically significant association between decreased PPP2R2C expression, disease relapse, and increased PCSM. Kaplan–Meier survival analysis indicated that low PPP2R2C expression in primary tumors is associated with decreased long-term survival. To our knowledge,

<table>
<thead>
<tr>
<th>Clinical outcome</th>
<th>PPP2R2C MNI</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemical relapse</td>
<td>No</td>
<td>2.25</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1.74</td>
</tr>
<tr>
<td>Distant metastases</td>
<td>No</td>
<td>2.32</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1.55</td>
</tr>
<tr>
<td>PCSM</td>
<td>No</td>
<td>2.21</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1.79</td>
</tr>
</tbody>
</table>
PPP2R2C-Mediated Prostate Cancer Growth

this is the first evidence suggesting that PPP2R2C loss may influence cancer-specific mortality.

PP2A is a known tumor suppressor and loss of PP2A phosphatase activity or altered substrate specificity has been shown to occur frequently in several human malignancies (10). Decreased PP2A function is sufficient to promote castration-resistant growth of the LNCaP cell line, and studies of the castration-resistant LNCaP derivative C4-2b, have reported lowered levels of the catalytic subunit PPP2CA (17). However, complete loss of PPP2CA expression can be detrimental to cancer cell growth and result in cell death (13), suggesting that PPP2CA expression plays a dual role in promoting survival and negatively regulating proliferation. Considering that the SV40ST oncogene promotes cell transformation by inhibiting B-subunit binding without initiating apoptosis (14), it is likely that loss of select PP2A B-subunits could alter PP2A substrate specificity and promote tumorigenesis while avoiding the apoptotic effect of total PPP2CA loss. Knockdown of individual PP2A regulatory B-subunits has shown differential effects on cell transformation (10, 13), an effect replicated in the HTRS experiments conducted in this study. Investigation into transforming B-subunit loss has shown patterns of growth pathway deregulation similar to those observed with inhibition of PP2A catalytic activity and those induced by SV40ST oncogene expression (13).

The effect of PPP2R2C expression on PP2A substrate specificity is largely unknown. However, PPP2R2C has been shown to negatively regulate the activity of the SRC oncogene in osteosarcoma cells (23). Surprisingly, PPP2R2C downregulation did not alter SRC pathway activity in prostate cancer cells. This discrepancy may be due to tissue-specific differences in subcellular localization of the PP2A complex. In osteosarcoma cells, investigators detected perinuclear expression of PPP2R2C (23). In contrast, PPP2R2C showed distinct nuclear localization in prostatic tissue. Tissue-specific variations in the subcellular localization of other PP2A B-regulatory subunits are widely reported; for example, PPP2R2A is detected in the cytoplasm of neural extracts (27), but expression is nuclear in the Jurkat cell line and rat epidermis (28, 29).

Further mechanistic studies are necessary to identify specific PP2A targets mediated by PPP2R2C expression in prostate carcinoma. Because PP2A directly regulates the activity of more than 50 kinases and other known proto-oncogenes (10, 11), this will likely require extensive proteomics-based experiments with an emphasis on deregulated survival and growth pathways found in clinical CRPC. The promotion of CRPC growth via decreased PPP2R2C expression provides an important example, supported by in vivo patient outcomes, of prostate cancer survival pathways that do not function through increased AR activity, but instead through the deregulation of existing signal transduction pathways. The identification of pharmacologic inhibitors of PPP2R2C complexes, or the growth pathway(s) activated by PPP2R2C loss may prove useful as a therapeutic in men with CRPC, or as neoadjuvant therapy in men with downregulated PPP2R2C in primary disease.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: E.G. Bluemn, C.Grandori, P. S. Nelson Development of methodology: E.G. Bluemn, D. Lewinshtein, J. Antin, P. S. Nelson Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.G. Bluemn, E. S. Spencer, D. Lewinshtein, E. Mostaghel, X. Zhang, C. Grandori, C. Porter, P. S. Nelson Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.G. Bluemn, E. S. Spencer, B. Mecham, R. R. Gordon, I. Coleman, C. Grandori, P. S. Nelson Writing, review, and/or revision of the manuscript: E.G. Bluemn, E. S. Spencer, R. R. Gordon, I. Coleman, E. Mostaghel, C. Porter, P. S. Nelson Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.G. Bluemn, E. S. Spencer, I. Coleman, P. S. Nelson Study supervision: P. S. Nelson

Acknowledgments

The authors thank Phil Febbo and Robin Tharakan for helpful discussions. The authors also thank Jared Lucas for assistance with immunohistochemistry.

Grant Support

This research was supported by SRC1CA146849, the Pacific Northwest SPORE in Prostate Cancer P50CA097186, the Prostate Cancer Foundation, and CDMRP Award PC093373P1. E.G. Bluemn was supported by Department of Defense Prostate Cancer Research Program Predoctoral Training Award (W81XWH-10-1-0133).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 26, 2012; revised February 20, 2013; accepted February 20, 2013; published OnlineFirst March 14, 2013.

References


www.aacjr.org Mol Cancer Res; 11(6) June 2013 577

Published OnlineFirst March 14, 2013; DOI: 10.1158/1541-7786.MCR-12-0710

Downloaded from mcr.aacrjournals.org on April 20, 2017. © 2013 American Association for Cancer Research.


PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality

Eric G. Bluemn, Elysia Sophie Spencer, Brigham Mecham, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-12-0710

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2013/03/19/1541-7786.MCR-12-0710.DC1

Cited articles
This article cites 29 articles, 12 of which you can access for free at:
http://mcr.aacrjournals.org/content/11/6/568.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.